Public Employees Retirement Association of Colorado Purchases 18,995 Shares of Incyte Co. (NASDAQ:INCY)

Public Employees Retirement Association of Colorado lifted its position in shares of Incyte Co. (NASDAQ:INCYFree Report) by 514.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,688 shares of the biopharmaceutical company’s stock after acquiring an additional 18,995 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Incyte were worth $1,425,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in INCY. Cape Investment Advisory Inc. purchased a new stake in Incyte during the 4th quarter valued at $25,000. Larson Financial Group LLC boosted its position in shares of Incyte by 4,220.0% during the fourth quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 422 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Incyte during the fourth quarter valued at $31,000. EverSource Wealth Advisors LLC increased its holdings in Incyte by 597.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 635 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 544 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its position in Incyte by 85.2% in the 4th quarter. Quadrant Capital Group LLC now owns 711 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 327 shares during the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Incyte

In other news, insider Thomas Tray sold 1,093 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $58.91, for a total value of $64,388.63. Following the sale, the insider now directly owns 21,634 shares in the company, valued at approximately $1,274,458.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 17.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on INCY shares. JMP Securities lowered shares of Incyte from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Jefferies Financial Group started coverage on shares of Incyte in a research report on Friday, February 23rd. They issued a “buy” rating and a $81.00 price target on the stock. Truist Financial reissued a “buy” rating and set a $83.00 price target (down previously from $84.00) on shares of Incyte in a report on Wednesday, May 1st. Oppenheimer decreased their price objective on Incyte from $92.00 to $84.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 24th. Finally, StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Incyte has a consensus rating of “Hold” and an average target price of $73.69.

Get Our Latest Stock Report on INCY

Incyte Trading Up 0.4 %

Shares of Incyte stock opened at $59.40 on Tuesday. The company has a quick ratio of 3.43, a current ratio of 3.47 and a debt-to-equity ratio of 0.01. The firm has a market cap of $13.34 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 1.27 and a beta of 0.74. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $67.36. The business has a 50-day moving average price of $55.29 and a 200-day moving average price of $58.10.

Incyte (NASDAQ:INCYGet Free Report) last released its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.31). The firm had revenue of $880.89 million for the quarter, compared to analysts’ expectations of $935.85 million. Incyte had a net margin of 19.78% and a return on equity of 12.83%. Equities research analysts anticipate that Incyte Co. will post 3.57 EPS for the current fiscal year.

Incyte Profile

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Read More

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.